Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
CHEST Journal. 2018 Dec; 154(6):1371–1378
A study team including several Analysis Group researchers has published the results of its work comparing the cost impacts of continued anticoagulation therapy with rivaroxaban versus aspirin. Managing Principal Patrick Lefebvre, Vice President François Laliberté, and Associate Dominique Lejeune contributed to “Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population,” published in CHEST Journal, the official publication of the American College of Chest Physicians.
The research team calculated total health care costs associated with rivaroxaban and aspirin from combined estimates of clinical event costs and drug costs from a US managed care perspective. The team found that continued therapy with rivaroxaban at two different doses was associated with lower clinical event costs than aspirin. The higher cost of the drug itself resulted in higher total costs, but the cost difference could be more than offset with a 15% drug discount. Clinical event rates for recurrent pulmonary embolism, recurrent deep vein thrombosis (DVT), all-cause mortality, and bleeding were obtained from EINSTEIN-CHOICE.